The results indicated IDH1 mutate, 1P19 codeletion, ATRX and MGMT as robust favorable clinical prognostic indicators, while PCK2 along with age (PCK2, TCGA: P<0.0001, CGGA: P<0.0001) serve as indicators for poor survival time in glioma patients. This evidence concerns the gene MGMT and central nervous system cancer.